Cell & Gene: The Podcast

Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye

Erin Harris

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 28:04

We love to hear from our listeners. Send us a message.

On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye explains how trials, regulatory flexibility, and optimized manufacturing could make it possible to treat many genetic variants efficiently and cost-effectively. Ultimately, Aurora aims to build a repeatable model that expands gene editing access to larger rare-disease populations while keeping patients at the center of development.

Subscribe to the podcast!
Apple  |  SpotifyYouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.